Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models.

Melchers MJ, Teague J, Warn P, Hansen J, Bernardini F, Wach A, Obrecht D, Dale GE, Mouton JW.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01699-18. doi: 10.1128/AAC.01699-18. Print 2019 Mar.

PMID:
30642931
2.

Infection Augments Expression of Mechanosensing Piezo1 Channels in Amyloid Plaque-Reactive Astrocytes.

Velasco-Estevez M, Mampay M, Boutin H, Chaney A, Warn P, Sharp A, Burgess E, Moeendarbary E, Dev KK, Sheridan GK.

Front Aging Neurosci. 2018 Oct 22;10:332. doi: 10.3389/fnagi.2018.00332. eCollection 2018.

3.

Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei.

Lackner M, Birch M, Naschberger V, Grässle D, Beckmann N, Warn P, Gould J, Law D, Lass-Flörl C, Binder U.

J Antimicrob Chemother. 2018 Nov 1;73(11):3068-3073. doi: 10.1093/jac/dky329.

PMID:
30351438
4.

The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis.

Garvey EP, Sharp AD, Warn PA, Yates CM, Schotzinger RJ.

J Antimicrob Chemother. 2018 Oct 1;73(10):2815-2822. doi: 10.1093/jac/dky242.

PMID:
29947783
5.

Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae.

Everett M, Sprynski N, Coelho A, Castandet J, Bayet M, Bougnon J, Lozano C, Davies DT, Leiris S, Zalacain M, Morrissey I, Magnet S, Holden K, Warn P, De Luca F, Docquier JD, Lemonnier M.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00074-18. doi: 10.1128/AAC.00074-18. Print 2018 May.

6.

Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.

Corbett D, Wise A, Langley T, Skinner K, Trimby E, Birchall S, Dorali A, Sandiford S, Williams J, Warn P, Vaara M, Lister T.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00200-17. doi: 10.1128/AAC.00200-17. Print 2017 Aug.

7.

A single dose of epidermicin NI01 is sufficient to eradicate MRSA from the nares of cotton rats.

Halliwell S, Warn P, Sattar A, Derrick JP, Upton M.

J Antimicrob Chemother. 2017 Mar 1;72(3):778-781. doi: 10.1093/jac/dkw457.

8.

Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Warn P, Thommes P, Sattar A, Corbett D, Flattery A, Zhang Z, Black T, Hernandez LD, Therien AG.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6471-6482. doi: 10.1128/AAC.00974-16. Print 2016 Nov.

9.

Alternatives to antibiotics-a pipeline portfolio review.

Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH.

Lancet Infect Dis. 2016 Feb;16(2):239-51. doi: 10.1016/S1473-3099(15)00466-1. Epub 2016 Jan 13. Review.

PMID:
26795692
10.

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.

Corbett D, Wise A, Birchall S, Warn P, Baines SD, Crowther G, Freeman J, Chilton CH, Vernon J, Wilcox MH, Vickers RJ.

J Antimicrob Chemother. 2015;70(6):1751-6. doi: 10.1093/jac/dkv006. Epub 2015 Feb 3.

11.

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.

Sattar A, Thommes P, Payne L, Warn P, Vickers RJ.

J Antimicrob Chemother. 2015;70(6):1757-62. doi: 10.1093/jac/dkv005. Epub 2015 Feb 3.

12.

Aspergillus fumigatus proteases, Asp f 5 and Asp f 13, are essential for airway inflammation and remodelling in a murine inhalation model.

Namvar S, Warn P, Farnell E, Bromley M, Fraczek M, Bowyer P, Herrick S.

Clin Exp Allergy. 2015 May;45(5):982-993. doi: 10.1111/cea.12426.

PMID:
25270353
13.

DL-2-hydroxyisocaproic acid attenuates inflammatory responses in a murine Candida albicans biofilm model.

Nieminen MT, Hernandez M, Novak-Frazer L, Kuula H, Ramage G, Bowyer P, Warn P, Sorsa T, Rautemaa R.

Clin Vaccine Immunol. 2014 Sep;21(9):1240-5. doi: 10.1128/CVI.00339-14. Epub 2014 Jul 2.

14.

Streptococcus pneumoniae worsens cerebral ischemia via interleukin 1 and platelet glycoprotein Ibα.

Dénes Á, Pradillo JM, Drake C, Sharp A, Warn P, Murray KN, Rohit B, Dockrell DH, Chamberlain J, Casbolt H, Francis S, Martinecz B, Nieswandt B, Rothwell NJ, Allan SM.

Ann Neurol. 2014 May;75(5):670-83. doi: 10.1002/ana.24146. Epub 2014 Apr 14.

15.

MRSA decolonization of cotton rat nares by a combination treatment comprising lysostaphin and the antimicrobial peptide ranalexin.

Desbois AP, Sattar A, Graham S, Warn PA, Coote PJ.

J Antimicrob Chemother. 2013 Nov;68(11):2569-75. doi: 10.1093/jac/dkt243. Epub 2013 Jun 25.

PMID:
23800902
16.

Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.

Sudan A, Livermore J, Howard SJ, Al-Nakeeb Z, Sharp A, Goodwin J, Gregson L, Warn PA, Felton TW, Perfect JR, Harrison TS, Hope WW.

Antimicrob Agents Chemother. 2013 Jun;57(6):2793-800. doi: 10.1128/AAC.00216-13. Epub 2013 Apr 9.

17.

Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.

Livermore JL, Felton TW, Abbott J, Sharp A, Goodwin J, Gregson L, Warn PA, Howard SJ, Hope WW.

Antimicrob Agents Chemother. 2013 Jan;57(1):281-8. doi: 10.1128/AAC.01387-12. Epub 2012 Oct 31.

18.

The Aspergillus fumigatus dihydroxyacid dehydratase Ilv3A/IlvC is required for full virulence.

Oliver JD, Kaye SJ, Tuckwell D, Johns AE, Macdonald DA, Livermore J, Warn PA, Birch M, Bromley MJ.

PLoS One. 2012;7(9):e43559. doi: 10.1371/journal.pone.0043559. Epub 2012 Sep 18.

19.

Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.

Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Warn PA, Hope WW.

Antimicrob Agents Chemother. 2012 Oct;56(10):5180-5. doi: 10.1128/AAC.01111-12. Epub 2012 Jul 23.

20.

Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.

Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, Lass-Flörl C, Cuenca-Estrella M, Arendrup MC, Warn PA, Hope WW.

J Infect Dis. 2012 Aug 1;206(3):442-52. doi: 10.1093/infdis/jis372. Epub 2012 May 25.

PMID:
22634880
21.

Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.

Al-Nakeeb Z, Sudan A, Jeans AR, Gregson L, Goodwin J, Warn PA, Felton TW, Howard SJ, Hope WW.

Antimicrob Agents Chemother. 2012 Aug;56(8):4146-53. doi: 10.1128/AAC.00141-12. Epub 2012 May 21.

22.

The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.

Alsaadi M, Italia JL, Mullen AB, Ravi Kumar MN, Candlish AA, Williams RA, Shaw CD, Al Gawhari F, Coombs GH, Wiese M, Thomson AH, Puig-Sellart M, Wallace J, Sharp A, Wheeler L, Warn P, Carter KC.

J Control Release. 2012 Jun 28;160(3):685-91. doi: 10.1016/j.jconrel.2012.04.004. Epub 2012 Apr 10.

PMID:
22516093
23.

Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.

Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowiez M, Walsh TJ, Benjamin DK Jr, Hope WW.

Antimicrob Agents Chemother. 2012 Feb;56(2):708-14. doi: 10.1128/AAC.05826-11. Epub 2011 Nov 28.

24.

Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis.

McCulloch E, Ramage G, Rajendran R, Lappin DF, Jones B, Warn P, Shrief R, Kirkpatrick WR, Patterson TF, Williams C.

J Clin Pathol. 2012 Jan;65(1):83-6. doi: 10.1136/jcp.2011.090464. Epub 2011 Nov 2.

PMID:
22049217
25.

Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.

Italia JL, Sharp A, Carter KC, Warn P, Kumar MN.

PLoS One. 2011;6(10):e25744. doi: 10.1371/journal.pone.0025744. Epub 2011 Oct 6.

26.

Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter.

Albarrag AM, Anderson MJ, Howard SJ, Robson GD, Warn PA, Sanglard D, Denning DW.

Antimicrob Agents Chemother. 2011 Nov;55(11):5113-21. doi: 10.1128/AAC.00517-11. Epub 2011 Aug 29.

27.

Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW.

Antimicrob Agents Chemother. 2011 Oct;55(10):4880-7. doi: 10.1128/AAC.00621-11. Epub 2011 Aug 1.

28.

Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.

Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW.

Antimicrob Agents Chemother. 2011 Jul;55(7):3075-83. doi: 10.1128/AAC.01686-10. Epub 2011 Apr 18.

29.

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW.

J Infect Dis. 2011 May 1;203(9):1324-32. doi: 10.1093/infdis/jir023. Epub 2011 Feb 28.

30.

Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity.

Rajendran R, Mowat E, McCulloch E, Lappin DF, Jones B, Lang S, Majithiya JB, Warn P, Williams C, Ramage G.

Antimicrob Agents Chemother. 2011 May;55(5):2092-7. doi: 10.1128/AAC.01189-10. Epub 2011 Feb 14.

31.

Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice.

Slater JL, Gregson L, Denning DW, Warn PA.

Med Mycol. 2011 Apr;49 Suppl 1:S107-13. doi: 10.3109/13693786.2010.523852. Epub 2010 Oct 18.

PMID:
20950221
32.

Candida tropicalis in human disease.

Chai LY, Denning DW, Warn P.

Crit Rev Microbiol. 2010 Nov;36(4):282-98. doi: 10.3109/1040841X.2010.489506. Review.

PMID:
20883082
33.

Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplification.

Zhao Y, Park S, Warn P, Shrief R, Harrison E, Perlin DS.

J Clin Microbiol. 2010 Apr;48(4):1378-83. doi: 10.1128/JCM.02214-09. Epub 2010 Feb 3.

34.
35.

In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.

Verweij PE, González GM, Wiedrhold NP, Lass-Flörl C, Warn P, Heep M, Ghannoum MA, Guinea J.

J Chemother. 2009 Jun;21(3):272-81.

PMID:
19567347
36.

Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.

Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW.

Antimicrob Agents Chemother. 2009 Aug;53(8):3453-61. doi: 10.1128/AAC.01601-08. Epub 2009 May 18.

37.

Don't throw your blood clots away: use of blood clot may improve sensitivity of PCR diagnosis in invasive aspergillosis.

McCulloch E, Ramage G, Jones B, Warn P, Kirkpatrick WR, Patterson TF, Williams C.

J Clin Pathol. 2009 Jun;62(6):539-41. doi: 10.1136/jcp.2008.063321. Epub 2009 Feb 3.

PMID:
19190008
38.

Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.

Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA.

J Antimicrob Chemother. 2009 Jan;63(1):161-6. doi: 10.1093/jac/dkn431. Epub 2008 Nov 13.

39.

Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.

Hope WW, Warn PA, Sharp A, Reed P, Keevil B, Louie A, Walsh TJ, Denning DW, Drusano GL.

Antimicrob Agents Chemother. 2007 Oct;51(10):3760-2. Epub 2007 Aug 6.

40.

Aspergillus flavus: human pathogen, allergen and mycotoxin producer.

Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW.

Microbiology. 2007 Jun;153(Pt 6):1677-92. Review.

PMID:
17526826
41.

Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2).

Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, Chryssantou E, Warn P, Denning DW, Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M.

J Clin Microbiol. 2007 Jan;45(1):109-11. Epub 2006 Nov 8.

42.

Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.

Hope WW, Drusano GL, Moore CB, Sharp A, Louie A, Walsh TJ, Denning DW, Warn PA.

Antimicrob Agents Chemother. 2007 Jan;51(1):285-95. Epub 2006 Nov 6.

43.

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A, Heep M, Denning DW.

J Antimicrob Chemother. 2006 Dec;58(6):1198-207. Epub 2006 Oct 27.

PMID:
17071636
44.

Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.

Hope WW, Warn PA, Sharp A, Howard S, Kasai M, Louie A, Walsh TJ, Drusano GL, Denning DW.

Antimicrob Agents Chemother. 2006 Nov;50(11):3680-8. Epub 2006 Sep 5.

45.

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

Warn PA, Sharp A, Denning DW.

J Antimicrob Chemother. 2006 Jan;57(1):135-8. Epub 2005 Nov 10.

PMID:
16284102
46.
47.

Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.

Hope WW, Warn PA, Sharp A, Reed P, Keevil B, Louie A, Denning DW, Drusano GL.

J Infect Dis. 2005 Aug 15;192(4):673-80. Epub 2005 Jul 7.

PMID:
16028137
48.
49.

Inactivation of transcription factor gene ACE2 in the fungal pathogen Candida glabrata results in hypervirulence.

Kamran M, Calcagno AM, Findon H, Bignell E, Jones MD, Warn P, Hopkins P, Denning DW, Butler G, Rogers T, Mühlschlegel FA, Haynes K.

Eukaryot Cell. 2004 Apr;3(2):546-52.

50.

Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida.

Warn PA, Sharp A, Guinea J, Denning DW.

J Antimicrob Chemother. 2004 May;53(5):743-9. Epub 2004 Mar 24.

PMID:
15044422

Supplemental Content

Support Center